To our knowledge, this is the first exploratory study showing the association of the genetic variants DRD4-VNTR and DAT1-VNTR, together with an MLGP score analysis, with an increased risk of developing obesity, diastolic arterial hypertension, and hypertriglyceridemia in patients treated with SGAs. The gene discussed is SLC6A3; the disease is obesity disorder.